AIFA publishes the first report on the monitoring of expenditure and consumption of patent-expired non-biologic medicines. This new monitoring document complements the monitoring of biosimilar medicines, thus providing a clear and complete picture of these medicines in NHS.

The aim is to provide useful information to healthcare professionals who deal with monitoring and governance of pharmaceutical expenditure, to promote the use of patent-expired medicines, assess the effectiveness of regional tenders, identify opportunities of intervention and monitor the effects of the policies put in place.